Vonoprazan Fumarate API Market – GERD and Acid-Related Disorders Drive Growth

The vonoprazan fumarate API market is expanding as demand rises for innovative therapies targeting gastroesophageal reflux disease, gastric ulcers, duodenal ulcers, and erosive esophagitis. The market was valued at USD 1.25 billion in 2024 and is projected to increase from USD 1.43 billion in 2025 to USD 5.53 billion by 2035, at a CAGR of 14.51%.marketresearchfuture

Vonoprazan is a potassium-competitive acid blocker used in acid-related disease treatment. Its mechanism has attracted attention as healthcare providers and pharmaceutical companies explore alternatives to traditional proton pump inhibitor therapies.

The growing prevalence of GERD is a major market driver. The report notes that acid-related disorders are becoming more common, increasing the need for effective, convenient, and well-tolerated treatment options. Greater awareness among both clinicians and patients is also encouraging earlier consultation and treatment.

Oral dosage forms dominate the market because they are convenient, familiar, and suitable for long-term management of common gastrointestinal conditions. Injectable formulations are gaining interest because they can be relevant in acute-care settings or situations requiring more rapid therapeutic action.

Gastric ulcers are the largest application segment, supported by established treatment needs and a large patient population. Erosive esophagitis is the fastest-growing application because awareness, diagnosis, and treatment demand are increasing.

Generic APIs currently lead due to affordability and accessibility, while branded products are expected to grow quickly as pharmaceutical companies develop differentiated formulations and expand their product portfolios.

North America is the largest market, while Asia-Pacific is expected to grow rapidly through healthcare investment, rising awareness of digestive conditions, and strong pharmaceutical manufacturing. Key companies include Takeda, Hikma Pharmaceuticals, Mylan, Aurobindo Pharma, Sun Pharmaceutical Industries, Zydus Cadila, Lupin, and Sandoz.marketresearchfuture

Read more: Vonoprazan Fumarate API Market

People Also Ask

Q1. What is vonoprazan fumarate used for?
It is used in treatments for acid-related gastrointestinal conditions such as GERD, gastric ulcers, duodenal ulcers, and erosive esophagitis.

Q2. Why is the vonoprazan fumarate API market growing?
GERD prevalence, demand for alternatives to traditional acid-suppression therapies, formulation innovation, and healthcare investment are key drivers.

Tags: vonoprazan fumarate API, GERD treatment, gastric ulcer therapy, acid-related disorders, gastrointestinal drugs